Small intestinal mesenchymal tumor malignant can not be generalized, some studies have shown that localized small intestinal mesenchymal tumor patients 5-year survival rate of up to 72%, the emergence of distant metastases of small intestinal mesenchymal tumor patients, its 5-year survival rate is about 7%. The specific survival time of patients with small intestinal mesenchymal tumors is related to factors such as the location and size of the tumor, whether it is completely resected and the number of nuclear schizophrenic images in the high magnification field of view. Some studies have shown that the 5-year survival rate of localized small intestinal mesenchymal tumors can be up to 72%, while patients with small intestinal mesenchymal tumors that develop distant metastases have a 5-year survival rate of about 7%. With the increasing understanding of small intestinal mesenchymal tumors, surgical treatment combined with molecularly targeted drugs has significantly improved the survival rate of patients. In recent years, with the widespread use of imatinib, a tyrosine kinase inhibitor, in gastrointestinal mesenchymal tumors, the 5-year survival rate has been significantly improved. Patients diagnosed with small intestinal mesenchymal tumors are advised to consult a doctor promptly and actively cooperate with the doctor’s treatment in order to improve the prognosis and prolong the survival period.